Skip to Main Content

Knowledge Center


Respiratory Outcomes and Lung Transplantation in COVID-19 Patients

What does COVID-19 do to the lungs? 

In approximately 5% of COVID-19 infections, respiratory and multi-organ failure occurs, and it is likely that many more individuals with a history of severe lung disease caused by the SARS-CoV-2 virus will require lung transplantation in the years to come. Still, lung transplantation in COVID-19 patients is an option of last resort.

RGA's Hilary Henly explores respiratory failure from COVID-19, long-term health outcomes after infection, and assessment criteria for lung transplantation. 

See also: Respiratory Outcomes and Lung Transplantation in COVID-19 Patients

As the pandemic evolves, new implications and data-driven insights will continue to emerge, which RGA will continue to investigate. Please contact us for insights.

The Presenter

  • Hilary Henly
    Global Medical Researcher
    RGA International Reinsurance Company dac
    Send email >


Curious about RGA's medical insights?  Contact us to learn more. 

This video was developed in conjunction with actuview, the first permanent international media platform for actuaries ( actuview content reflects contributions from actuarial institutions, corporate partners and industry professionals. RGA is actuview’s sponsoring partner.
  • COVID-19
  • Henly
  • Hilary Henly
  • lung disease
  • lung transplantation
  • morbidity improvement
  • organ failure
  • pandemic
  • respiratory failure
  • SARS-CoV-2
  • SARS-CoV-2 morbidity
  • SARS-CoV-2 mortality